Don't forg_老虎社区_美港股上老虎

2021-12-30

Don't forget about $roku

2 Beaten-Down Cathie Wood Stocks That Could Be Bargain Buys for 2022<blockquote>2022年可能逢低买入的2只遭受重创的Cathie Wood股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":692109084,"tweetId":"692109084","gmtCreate":1640864587671,"gmtModify":1640864667499,"author":{"id":3568769977321272,"idStr":"3568769977321272","authorId":3568769977321272,"authorIdStr":"3568769977321272","name":"mark01bravz","avatar":"https://static.tigerbbs.com/a5b7674da5bdda08c302399c7d276a6c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3847,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Don't forget about $roku</body></html>","htmlText":"<html><head></head><body>Don't forget about $roku</body></html>","text":"Don't forget about $roku","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/692109084","repostId":1192818038,"repostType":4,"repost":{"id":"1192818038","kind":"news","pubTimestamp":1640848511,"share":"https://www.laohu8.com/m/news/1192818038?lang=zh_CN&edition=full","pubTime":"2021-12-30 15:15","market":"us","language":"en","title":"2 Beaten-Down Cathie Wood Stocks That Could Be Bargain Buys for 2022<blockquote>2022年可能逢低买入的2只遭受重创的Cathie Wood股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192818038","media":"Motley Fool","summary":"These stocks are trading near their 52-week lows but have tremendous long-term growth opportunities.","content":"<html><head></head><body>Key Points<blockquote><html><head></head><body>要点</body></html></blockquote><ul><li>Shares of Teladoc Health and DraftKings have been crashing this year.</li><li>Yet Teladoc is continuing to grow and generating positive free cash flow.</li><li>DraftKings is ideally positioned to cash in on a sports betting market still in its early stages.</li></ul>Cathie Wood knows growth stocks. And although some of her holdings aren&#39;t performing terribly well of late, that doesn&#39;t mean they have suddenly become bad buys. In the wake of interest rate increases possibly coming next year and COVID-19 cases spiking yet again, investors have put the brakes on growth stocks. The ARK Innovation ETF, which is synonymous with disruptive growth companies, has fallen 21% this year while the S&amp;P 500 has jumped by 27%.<blockquote><ul><li>Teladoc Health和DraftKings的股价今年一直在暴跌。</li><li>然而，Teladoc仍在继续增长并产生正的自由现金流。</li><li>DraftKings处于理想的位置，可以在仍处于早期阶段的体育博彩市场中获利。</li></ul>凯西·伍德了解成长型股票。尽管她持有的一些股票最近表现不佳，但这并不意味着它们突然变得不值得买入。在明年可能加息以及COVID-19病例再次激增之后，投资者已经对成长型股票踩下了刹车。The方舟创新ETF是颠覆性成长型公司的代名词，今年已下跌21%，而标普500已跃升27%。</blockquote>But the Innovation fund contains many top stocks that I wouldn&#39;t bet against over the long haul. Two of the most promising ones to consider as we head into 2022 are Teladoc Health(NYSE:TDOC) and DraftKings(NASDAQ:DKNG). At their current prices, these stocks could be bargains right now, and investors should take a close look as these levels might not last for long.<blockquote>但创新基金包含许多我不会长期做空的顶级股票。在我们进入2022年之际，最有希望考虑的两个问题是Teladoc健康（纽约证券交易所代码：TDOC）和DraftKing（纳斯达克：DKNG）。按照目前的价格，这些股票目前可能很便宜，投资者应该密切关注，因为这些水平可能不会持续太久。</blockquote><img src=\"https://static.tigerbbs.com/2111f5a9c4c88f14f694bbe8be2c6b08\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>1. Teladoc Health<blockquote>1.Teladoc健康</blockquote>It&#39;s amazing to see that Teladoc&#39;s share price has been cut in half this year. Down by more than 50%, it&#39;s a stock you might look at and think the business is in serious trouble to suffer such a fall. And while some losses may have been inevitable after last year&#39;s impressive performance, when the stock rose by nearly 140% (dwarfing the S&amp;P 500, which rose only 16%), this sell-off looks to be overdone.<blockquote>令人惊讶的是，Teladoc的股价今年已经腰斩。下跌超过50%，您可能会看到这只股票，并认为该公司因遭受如此下跌而陷入严重困境。尽管在去年令人印象深刻的表现之后，一些损失可能是不可避免的，当时该股上涨了近140%（使仅上涨16%的标普500相形见绌），但这种抛售似乎有些过头了。</blockquote>A big part of the reason Teladoc is likely down right now is its inclusion in the ARK ETF, which has drawn investor bearishness of late, plus an assumption that demand for telehealth might drop significantly once the pandemic is no longer a concern.<blockquote>Teladoc目前可能下跌的很大一部分原因是它被纳入ARK ETF，该ETF最近引起了投资者的看跌情绪，再加上人们认为一旦疫情不再令人担忧，对远程医疗的需求可能会大幅下降。</blockquote>The former is likely just a short-term trend as growth stocks typically are among the best-performing investments over time. And the latter isn&#39;t something I would be worried about at all. For one thing, telehealth is a more affordable option than in-person trips to the doctor&#39;s office (it&#39;s about half the cost), so there&#39;s plenty of incentive for employers to include it as part of healthcare options for their employees.<blockquote>前者可能只是短期趋势，因为随着时间的推移，成长型股票通常是表现最好的投资之一。后者根本不是我担心的事情。一方面，远程医疗比亲自去医生办公室更实惠（大约是费用的一半），因此雇主有足够的动力将其作为员工医疗保健选择的一部分。</blockquote>And the convenience factor shouldn&#39;t be overlooked either. Some patients aren&#39;t mobile, and a quick telehealth visit can spot issues before they become much more serious. That&#39;s where merging with chronic-care company Livongo Health in 2020 was a great move for Teladoc. The transaction only closed in October 2020 and is in its early innings, but this is an area that could take off in the long term.<blockquote>便利因素也不应该被忽视。一些患者不能移动，快速的远程医疗访问可以在问题变得更加严重之前发现问题。这就是Teladoc在2020年与慢性护理公司Livongo Health合并是一个伟大的举措。该交易于2020年10月才完成，目前还处于早期阶段，但从长远来看，这是一个可以腾飞的领域。</blockquote>Measured by its price-to-sales ratio, Teladoc Health is trading at its lowest levels all year. Many analysts see its shares rising to more than $150 -- and some even think it could go over $200.<blockquote>以市销率衡量，Teladoc Health的交易价格处于全年最低水平。许多分析师认为其股价将升至150美元以上，有些人甚至认为其股价可能会超过200美元。</blockquote><img src=\"https://static.tigerbbs.com/037c08e7226ec84eb6448ca4daf784d3\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/>TDOC PS RATIO DATA BY YCHARTS.<blockquote>YCHARTS提供的TDOC PS比率数据。</blockquote>Teladoc&#39;s business is unprofitable right now, but the company has generated positive free cash flow for two straight periods and looks to be on the right track. Over the first nine months of 2021, it has generated $1.5 billion in revenue, more than double the $710 million it reported a year earlier (largely due to the inclusion of Livongo in these numbers).<blockquote>Teladoc的业务目前尚未盈利，但该公司已连续两个时期产生正的自由现金流，并且看起来走在正确的轨道上。2021年前9个月，它创造了15亿美元的收入，是一年前报告的7.1亿美元的两倍多（主要是由于这些数字中包含了Livongo）。</blockquote>Buying now while the bears are keeping the healthcare stock down near its lows could be a move you thank yourself for in the future.<blockquote>当空头将医疗保健股压低至低点附近时，现在买入可能是您未来值得感谢的举动。</blockquote>2. DraftKings<blockquote>2.DraftKings</blockquote>Another top growth stock you&#39;ll find in the ARK ETF is DraftKings. The entertainment and gaming company is aggressively pursuing growth opportunities in the sports betting market. Sports betting isn&#39;t legal in every state, but that may just be a matter of time. Since the U.S. government lifted the federal ban on sports betting in 2018, states have been legalizing the practice -- and now more than 20 of them permit some form of betting on sports.<blockquote>ARK ETF中另一只增长最快的股票是DraftKings。这家娱乐和游戏公司正在积极寻求体育博彩市场的增长机会。体育博彩并非在每个州都是合法的，但这可能只是时间问题。自美国政府在2018年解除联邦体育博彩禁令以来，各州一直在将这种做法合法化，现在其中20多个州允许某种形式的体育博彩。</blockquote>DraftKings is arguably an industry leader here, offering online casino products, a sportsbook, and fantasy sports products as well. For the period ended Sept. 30, it generated $212.8 million in revenue, up more than 60% from the year-ago period.<blockquote>DraftKings可以说是这里的行业领导者，提供在线赌场产品、体育书籍和梦幻体育产品。截至9月30日的期间，该公司实现收入2.128亿美元，比去年同期增长60%以上。</blockquote>Like Teladoc, DraftKings isn&#39;t profitable today, but the long-term trajectory of its business looks solid. CEO Jason Robins sees a two- to three-year window before the company&#39;s investments in new states result in profitability. For investors, that will require patience, especially since acquiring companies (which DraftKings likes to do) can lengthen the time to profitability even further. Plus, eliminating redundancies and fine-tuning operations are not always easy.<blockquote>与Teladoc一样，DraftKings目前尚未盈利，但其业务的长期轨迹看起来很稳健。首席执行官杰森·罗宾斯(Jason Robins)认为，公司在新州的投资需要两到三年的时间才能实现盈利。对于投资者来说，这需要耐心，特别是因为收购公司（DraftKings喜欢这样做）可以进一步延长盈利时间。此外，消除冗余和微调操作并不总是容易的。</blockquote>One of the company&#39;s more notable deals was the announcement in August that it will acquire Golden Nugget Online Gaming for $1.56 billion. Funded entirely through shares, the transaction will have a dilutive effect on the stock price (the transaction will close in the first quarter of 2022). But with 5 million customers to bring to DraftKings, plus Golden Nugget&#39;s $36 million profit on revenue of $117 million over the past four quarters, there are many positives investors can pull from this deal.<blockquote>该公司最引人注目的交易之一是八月份宣布将收购金块在线游戏15.6亿美元。该交易完全通过股票融资，将对股价产生摊薄效应（交易将于2022年第一季度完成）。但DraftKings将获得500万客户，再加上Golden Nugget在过去四个季度1.17亿美元的收入中获得3600万美元的利润，投资者可以从这笔交易中获得许多积极因素。</blockquote>Year to date, DraftKings stock is down around 40%. and most of those losses have come in just the past few months as growth stocks have come under pressure. It is trading around its 52-week lows, and so this is another attractive option to add to your portfolio for the new year.<blockquote>今年迄今为止，DraftKings股价已下跌约40%。由于成长型股票面临压力，其中大部分损失发生在过去几个月。它的交易价格在52周低点附近，因此这是新年投资组合中另一个有吸引力的选择。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Beaten-Down Cathie Wood Stocks That Could Be Bargain Buys for 2022<blockquote>2022年可能逢低买入的2只遭受重创的Cathie Wood股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Beaten-Down Cathie Wood Stocks That Could Be Bargain Buys for 2022<blockquote>2022年可能逢低买入的2只遭受重创的Cathie Wood股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-12-30 15:15\n\n</h4>\n</header>\n<article>\n<html><head></head><body>Key Points<blockquote><html><head></head><body>要点</body></html></blockquote><ul><li>Shares of Teladoc Health and DraftKings have been crashing this year.</li><li>Yet Teladoc is continuing to grow and generating positive free cash flow.</li><li>DraftKings is ideally positioned to cash in on a sports betting market still in its early stages.</li></ul>Cathie Wood knows growth stocks. And although some of her holdings aren&#39;t performing terribly well of late, that doesn&#39;t mean they have suddenly become bad buys. In the wake of interest rate increases possibly coming next year and COVID-19 cases spiking yet again, investors have put the brakes on growth stocks. The ARK Innovation ETF, which is synonymous with disruptive growth companies, has fallen 21% this year while the S&amp;P 500 has jumped by 27%.<blockquote><ul><li>Teladoc Health和DraftKings的股价今年一直在暴跌。</li><li>然而，Teladoc仍在继续增长并产生正的自由现金流。</li><li>DraftKings处于理想的位置，可以在仍处于早期阶段的体育博彩市场中获利。</li></ul>凯西·伍德了解成长型股票。尽管她持有的一些股票最近表现不佳，但这并不意味着它们突然变得不值得买入。在明年可能加息以及COVID-19病例再次激增之后，投资者已经对成长型股票踩下了刹车。The方舟创新ETF是颠覆性成长型公司的代名词，今年已下跌21%，而标普500已跃升27%。</blockquote>But the Innovation fund contains many top stocks that I wouldn&#39;t bet against over the long haul. Two of the most promising ones to consider as we head into 2022 are Teladoc Health(NYSE:TDOC) and DraftKings(NASDAQ:DKNG). At their current prices, these stocks could be bargains right now, and investors should take a close look as these levels might not last for long.<blockquote>但创新基金包含许多我不会长期做空的顶级股票。在我们进入2022年之际，最有希望考虑的两个问题是Teladoc健康（纽约证券交易所代码：TDOC）和DraftKing（纳斯达克：DKNG）。按照目前的价格，这些股票目前可能很便宜，投资者应该密切关注，因为这些水平可能不会持续太久。</blockquote><img src=\"https://static.tigerbbs.com/2111f5a9c4c88f14f694bbe8be2c6b08\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>1. Teladoc Health<blockquote>1.Teladoc健康</blockquote>It&#39;s amazing to see that Teladoc&#39;s share price has been cut in half this year. Down by more than 50%, it&#39;s a stock you might look at and think the business is in serious trouble to suffer such a fall. And while some losses may have been inevitable after last year&#39;s impressive performance, when the stock rose by nearly 140% (dwarfing the S&amp;P 500, which rose only 16%), this sell-off looks to be overdone.<blockquote>令人惊讶的是，Teladoc的股价今年已经腰斩。下跌超过50%，您可能会看到这只股票，并认为该公司因遭受如此下跌而陷入严重困境。尽管在去年令人印象深刻的表现之后，一些损失可能是不可避免的，当时该股上涨了近140%（使仅上涨16%的标普500相形见绌），但这种抛售似乎有些过头了。</blockquote>A big part of the reason Teladoc is likely down right now is its inclusion in the ARK ETF, which has drawn investor bearishness of late, plus an assumption that demand for telehealth might drop significantly once the pandemic is no longer a concern.<blockquote>Teladoc目前可能下跌的很大一部分原因是它被纳入ARK ETF，该ETF最近引起了投资者的看跌情绪，再加上人们认为一旦疫情不再令人担忧，对远程医疗的需求可能会大幅下降。</blockquote>The former is likely just a short-term trend as growth stocks typically are among the best-performing investments over time. And the latter isn&#39;t something I would be worried about at all. For one thing, telehealth is a more affordable option than in-person trips to the doctor&#39;s office (it&#39;s about half the cost), so there&#39;s plenty of incentive for employers to include it as part of healthcare options for their employees.<blockquote>前者可能只是短期趋势，因为随着时间的推移，成长型股票通常是表现最好的投资之一。后者根本不是我担心的事情。一方面，远程医疗比亲自去医生办公室更实惠（大约是费用的一半），因此雇主有足够的动力将其作为员工医疗保健选择的一部分。</blockquote>And the convenience factor shouldn&#39;t be overlooked either. Some patients aren&#39;t mobile, and a quick telehealth visit can spot issues before they become much more serious. That&#39;s where merging with chronic-care company Livongo Health in 2020 was a great move for Teladoc. The transaction only closed in October 2020 and is in its early innings, but this is an area that could take off in the long term.<blockquote>便利因素也不应该被忽视。一些患者不能移动，快速的远程医疗访问可以在问题变得更加严重之前发现问题。这就是Teladoc在2020年与慢性护理公司Livongo Health合并是一个伟大的举措。该交易于2020年10月才完成，目前还处于早期阶段，但从长远来看，这是一个可以腾飞的领域。</blockquote>Measured by its price-to-sales ratio, Teladoc Health is trading at its lowest levels all year. Many analysts see its shares rising to more than $150 -- and some even think it could go over $200.<blockquote>以市销率衡量，Teladoc Health的交易价格处于全年最低水平。许多分析师认为其股价将升至150美元以上，有些人甚至认为其股价可能会超过200美元。</blockquote><img src=\"https://static.tigerbbs.com/037c08e7226ec84eb6448ca4daf784d3\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/>TDOC PS RATIO DATA BY YCHARTS.<blockquote>YCHARTS提供的TDOC PS比率数据。</blockquote>Teladoc&#39;s business is unprofitable right now, but the company has generated positive free cash flow for two straight periods and looks to be on the right track. Over the first nine months of 2021, it has generated $1.5 billion in revenue, more than double the $710 million it reported a year earlier (largely due to the inclusion of Livongo in these numbers).<blockquote>Teladoc的业务目前尚未盈利，但该公司已连续两个时期产生正的自由现金流，并且看起来走在正确的轨道上。2021年前9个月，它创造了15亿美元的收入，是一年前报告的7.1亿美元的两倍多（主要是由于这些数字中包含了Livongo）。</blockquote>Buying now while the bears are keeping the healthcare stock down near its lows could be a move you thank yourself for in the future.<blockquote>当空头将医疗保健股压低至低点附近时，现在买入可能是您未来值得感谢的举动。</blockquote>2. DraftKings<blockquote>2.DraftKings</blockquote>Another top growth stock you&#39;ll find in the ARK ETF is DraftKings. The entertainment and gaming company is aggressively pursuing growth opportunities in the sports betting market. Sports betting isn&#39;t legal in every state, but that may just be a matter of time. Since the U.S. government lifted the federal ban on sports betting in 2018, states have been legalizing the practice -- and now more than 20 of them permit some form of betting on sports.<blockquote>ARK ETF中另一只增长最快的股票是DraftKings。这家娱乐和游戏公司正在积极寻求体育博彩市场的增长机会。体育博彩并非在每个州都是合法的，但这可能只是时间问题。自美国政府在2018年解除联邦体育博彩禁令以来，各州一直在将这种做法合法化，现在其中20多个州允许某种形式的体育博彩。</blockquote>DraftKings is arguably an industry leader here, offering online casino products, a sportsbook, and fantasy sports products as well. For the period ended Sept. 30, it generated $212.8 million in revenue, up more than 60% from the year-ago period.<blockquote>DraftKings可以说是这里的行业领导者，提供在线赌场产品、体育书籍和梦幻体育产品。截至9月30日的期间，该公司实现收入2.128亿美元，比去年同期增长60%以上。</blockquote>Like Teladoc, DraftKings isn&#39;t profitable today, but the long-term trajectory of its business looks solid. CEO Jason Robins sees a two- to three-year window before the company&#39;s investments in new states result in profitability. For investors, that will require patience, especially since acquiring companies (which DraftKings likes to do) can lengthen the time to profitability even further. Plus, eliminating redundancies and fine-tuning operations are not always easy.<blockquote>与Teladoc一样，DraftKings目前尚未盈利，但其业务的长期轨迹看起来很稳健。首席执行官杰森·罗宾斯(Jason Robins)认为，公司在新州的投资需要两到三年的时间才能实现盈利。对于投资者来说，这需要耐心，特别是因为收购公司（DraftKings喜欢这样做）可以进一步延长盈利时间。此外，消除冗余和微调操作并不总是容易的。</blockquote>One of the company&#39;s more notable deals was the announcement in August that it will acquire Golden Nugget Online Gaming for $1.56 billion. Funded entirely through shares, the transaction will have a dilutive effect on the stock price (the transaction will close in the first quarter of 2022). But with 5 million customers to bring to DraftKings, plus Golden Nugget&#39;s $36 million profit on revenue of $117 million over the past four quarters, there are many positives investors can pull from this deal.<blockquote>该公司最引人注目的交易之一是八月份宣布将收购金块在线游戏15.6亿美元。该交易完全通过股票融资，将对股价产生摊薄效应（交易将于2022年第一季度完成）。但DraftKings将获得500万客户，再加上Golden Nugget在过去四个季度1.17亿美元的收入中获得3600万美元的利润，投资者可以从这笔交易中获得许多积极因素。</blockquote>Year to date, DraftKings stock is down around 40%. and most of those losses have come in just the past few months as growth stocks have come under pressure. It is trading around its 52-week lows, and so this is another attractive option to add to your portfolio for the new year.<blockquote>今年迄今为止，DraftKings股价已下跌约40%。由于成长型股票面临压力，其中大部分损失发生在过去几个月。它的交易价格在52周低点附近，因此这是新年投资组合中另一个有吸引力的选择。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/12/29/2-beaten-down-cathie-wood-stocks-that-could-be-bar/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","DKNG":"DraftKings Inc."},"source_url":"https://www.fool.com/investing/2021/12/29/2-beaten-down-cathie-wood-stocks-that-could-be-bar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192818038","content_text":"Key PointsShares of Teladoc Health and DraftKings have been crashing this year.Yet Teladoc is continuing to grow and generating positive free cash flow.DraftKings is ideally positioned to cash in on a sports betting market still in its early stages.Cathie Wood knows growth stocks. And although some of her holdings aren't performing terribly well of late, that doesn't mean they have suddenly become bad buys. In the wake of interest rate increases possibly coming next year and COVID-19 cases spiking yet again, investors have put the brakes on growth stocks. The ARK Innovation ETF, which is synonymous with disruptive growth companies, has fallen 21% this year while the S&P 500 has jumped by 27%.But the Innovation fund contains many top stocks that I wouldn't bet against over the long haul. Two of the most promising ones to consider as we head into 2022 are Teladoc Health(NYSE:TDOC) and DraftKings(NASDAQ:DKNG). At their current prices, these stocks could be bargains right now, and investors should take a close look as these levels might not last for long.IMAGE SOURCE: GETTY IMAGES.1. Teladoc HealthIt's amazing to see that Teladoc's share price has been cut in half this year. Down by more than 50%, it's a stock you might look at and think the business is in serious trouble to suffer such a fall. And while some losses may have been inevitable after last year's impressive performance, when the stock rose by nearly 140% (dwarfing the S&P 500, which rose only 16%), this sell-off looks to be overdone.A big part of the reason Teladoc is likely down right now is its inclusion in the ARK ETF, which has drawn investor bearishness of late, plus an assumption that demand for telehealth might drop significantly once the pandemic is no longer a concern.The former is likely just a short-term trend as growth stocks typically are among the best-performing investments over time. And the latter isn't something I would be worried about at all. For one thing, telehealth is a more affordable option than in-person trips to the doctor's office (it's about half the cost), so there's plenty of incentive for employers to include it as part of healthcare options for their employees.And the convenience factor shouldn't be overlooked either. Some patients aren't mobile, and a quick telehealth visit can spot issues before they become much more serious. That's where merging with chronic-care company Livongo Health in 2020 was a great move for Teladoc. The transaction only closed in October 2020 and is in its early innings, but this is an area that could take off in the long term.Measured by its price-to-sales ratio, Teladoc Health is trading at its lowest levels all year. Many analysts see its shares rising to more than $150 -- and some even think it could go over $200.TDOC PS RATIO DATA BY YCHARTS.Teladoc's business is unprofitable right now, but the company has generated positive free cash flow for two straight periods and looks to be on the right track. Over the first nine months of 2021, it has generated $1.5 billion in revenue, more than double the $710 million it reported a year earlier (largely due to the inclusion of Livongo in these numbers).Buying now while the bears are keeping the healthcare stock down near its lows could be a move you thank yourself for in the future.2. DraftKingsAnother top growth stock you'll find in the ARK ETF is DraftKings. The entertainment and gaming company is aggressively pursuing growth opportunities in the sports betting market. Sports betting isn't legal in every state, but that may just be a matter of time. Since the U.S. government lifted the federal ban on sports betting in 2018, states have been legalizing the practice -- and now more than 20 of them permit some form of betting on sports.DraftKings is arguably an industry leader here, offering online casino products, a sportsbook, and fantasy sports products as well. For the period ended Sept. 30, it generated $212.8 million in revenue, up more than 60% from the year-ago period.Like Teladoc, DraftKings isn't profitable today, but the long-term trajectory of its business looks solid. CEO Jason Robins sees a two- to three-year window before the company's investments in new states result in profitability. For investors, that will require patience, especially since acquiring companies (which DraftKings likes to do) can lengthen the time to profitability even further. Plus, eliminating redundancies and fine-tuning operations are not always easy.One of the company's more notable deals was the announcement in August that it will acquire Golden Nugget Online Gaming for $1.56 billion. Funded entirely through shares, the transaction will have a dilutive effect on the stock price (the transaction will close in the first quarter of 2022). But with 5 million customers to bring to DraftKings, plus Golden Nugget's $36 million profit on revenue of $117 million over the past four quarters, there are many positives investors can pull from this deal.Year to date, DraftKings stock is down around 40%. and most of those losses have come in just the past few months as growth stocks have come under pressure. It is trading around its 52-week lows, and so this is another attractive option to add to your portfolio for the new year.","news_type":1,"symbols_score_info":{"TDOC":0.9,"DKNG":0.9}},"isVote":1,"tweetType":1,"viewCount":2750,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":21,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/692109084"}